### Indication
- Parkinson disease  

**INN**
- Biperiden

**Medicine type**
- Chemical agent

**List type**
- Core

**Formulations**
- Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)  
- Oral > Solid: 2 mg tablet (hydrochloride)

**EML status history**
- First added in 1982 (TRS 685)  
- Changed in 2005 (TRS 933)  
- Changed in 2013 (TRS 985)  
- Changed in 2021 (TRS 1035)

**Sex**
- All

**Age**
- Adolescents and adults

**Therapeutic alternatives**
- trihexyphenidyl (ATC codes: N04AA01)

**Patent information**
- Patents have expired in most jurisdictions
  - Read more about patents.

**Wikipedia**
- Biperiden

**DrugBank**
- Biperiden

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended trihexyphenidyl be specified as a therapeutic alternative under the square box listing for biperiden on the EML.